PAR · ALMDT.PA
Median Technologies S.A.
€4.26-€0.12 (-2.63%)
Median Technologies S.A.’s quoted price sits in the lower half of its reported 52-week range, 41.47% below the high.
Loading market information…
PAR · AB.PA · EUR
Stock price, earnings
Quote as of Oct 29, 2026, 04:35 PM UTC. Cached market data; not a live quote.
One-year closing-price history · EUR. Historical prices are not a forecast.
AB Science S.A.’s quoted price sits in the lower half of its reported 52-week range, 65.96% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
AB Science S.A.’s next earnings report is currently expected on Apr 23, 2027, with estimated earnings per share of -€0.07. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow AB Science S.A.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
AB Science S.A. is a pharmaceutical company dedicated to the discovery, development, and commercialization of protein kinase inhibitors for applications in both human and animal health. Its primary drug candidate, masitinib, a tyrosine kinase inhibitor, is currently undergoing late-stage (Phase III) clinical investigations for a range of serious conditions including prostate cancer, pancreatic cancer, amyotrophic lateral sclerosis (ALS), multiple sclerosis, Alzheimer's disease, severe asthma, and mastocytosis. Additionally, masitinib is being evaluated in Phase II clinical trials for the treatment of Covid-19. The company's pipeline also features AB8939, a synthetic microtubule destabilizer aimed at treating acute myeloid leukemia, and AB20001, which is in Phase 2 trials to assess the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients experiencing moderate to severe COVID-19. Masitinib is sold under the brand name Masivet in the European market. AB Science S.A. was founded in 2001 and is based in Paris, France.
Latest available per-share figures in EUR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:25 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| €448.00K |
| Apr 28, 2023 | Apr 28, 2023 | -€0.14+81.86% vs estimate | €329.00K-79.44% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
€4.26-€0.12 (-2.63%)
Median Technologies S.A.’s quoted price sits in the lower half of its reported 52-week range, 41.47% below the high.
€2.81€0.00 (0.0%)
Affluent Medical S.A.’s quoted price sits in the upper half of its reported 52-week range, 4.75% below the high.
€16,100.00€0.00 (0.0%)
Eurofins-Cerep S.A.’s quoted price sits in the lower half of its reported 52-week range, 21.84% below the high.
€1.27+€0.02 (+1.59%)
Crossject S.A.’s quoted price sits in the lower half of its reported 52-week range, 52.81% below the high.
€0.74+€0.05 (+7.4%)
Theraclion S.A.’s quoted price sits in the upper half of its reported 52-week range, 20.43% below the high.
€8.90+€0.10 (+1.14%)
Sensorion S.A.’s quoted price sits in the lower half of its reported 52-week range, 77.97% below the high.
€0.16+€0.01 (+4.44%)
Klea Holding’s quoted price sits in the lower half of its reported 52-week range, 38.42% below the high.
€0.39-€0.00 (-0.13%)
Fermentalg’s quoted price sits in the lower half of its reported 52-week range, 39.14% below the high.
